Protocol digest of a phase III trial to evaluate the efficacy of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA Trial)

被引：3

作者：

Mizusawa, Junki ^{[1
]}

Tokunaga, Masanori ^{[2
]}

Machida, Nozomu ^{[3
]}

Yabusaki, Hiroshi ^{[4
]}

Kawabata, Ryohei ^{[5
]}

Imamura, Hiroshi ^{[6
]}

Kinoshita, Takahiro ^{[7
]}

Nomura, Takashi ^{[8
]}

Nunobe, Souya ^{[9
]}

Tsuji, Kunihiro ^{[10
]}

Katayama, Hiroshi ^{[1
]}

Fukuda, Haruhiko ^{[1
]}

Boku, Narikazu ^{[11
]}

Yoshikawa, Takaki ^{[12
]}

Terashima, Masanori ^{[13
]}

机构：

[1] Natl Canc Ctr, Japan Clin Oncol Grp, Data Ctr, Operat Off, Tokyo, Japan

[2] Tokyo Med & Dent Univ, Dept Gastrointestinal Surg, Tokyo, Japan

[3] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[4] Niigata Canc Ctr Hosp, Dept Gastroenterol Surg, Niigata, Japan

[5] Osaka Rosai Hosp, Dept Surg, Osaka, Japan

[6] Toyonaka City Hosp, Dept Surg, Osaka, Japan

[7] Natl Canc Ctr Hosp East, Dept Gastr Surg, Kashiwa, Chiba, Japan

[8] Yamagata Prefectural Cent Hosp, Dept Surg, Yamagata, Japan

[9] Canc Inst Hosp, Dept Gastr Surg, Tokyo, Japan

[10] Ishikawa Prefectural Cent Hosp, Dept Gastroenterol, Kanazawa, Ishikawa, Japan

[11] Univ Tokyo, IMSUT Hosp, Inst Med Sci, Dept Oncol & Gen Med, Tokyo, Japan

[12] Natl Canc Ctr, Dept Gastr Surg, Tokyo, Japan

[13] Shizuoka Canc Ctr, Dept Gastr Surg, Shizuoka, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 53卷 / 02期

关键词：

gastric cancer; preoperative chemotherapy; LYMPH-NODE DISSECTION; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; CISPLATIN; SURGERY; SURVIVAL;

D O I：

10.1093/jjco/hyac154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In Japan, postoperative chemotherapy is a standard care for stage II/III gastric cancer after curative resection with D2 lymph node dissection, and the clinical outcomes of patients with stage Ill gastric cancer are unsatisfactory. A combination of oral S-1 and oxaliplatin, that is the standard chemotherapy regimen for unresectable advanced/recurrent gastric cancer associated with a high response rate, was considered the most promising preoperative chemotherapy regimen. This randomized phase Ill trial was started in September 2016 to confirm the superiority of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative chemotherapy compared with D2 gastrectomy with postoperative chemotherapy for patients with clinical T3-4N1-3 M0 locally advanced gastric cancer in terms of overall survival. A total of 470 patients will be enrolled from 63 hospitals in Japan for 8.5 years. This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031180350 [https://jrct.niph.go.jp/latest-detail/jRCTs031180350].

引用

页码：168 / 173

页数：6

共 50 条

[21] A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer
Jun Higashijima
Takuya Tokunaga
Toshiaki Yoshimoto
Shohei Eto
Hideya Kashihara
Chie Takasu
Masaaki Nishi
Kozo Yoshikawa
Hiroshi Okitsu
Masashi Ishikawa
Hidenori Miyake
Toshiyuki Yagi
Toru Kono
Mitsuo Shimada
International Journal of Clinical Oncology, 2021, 26 : 875 - 882
[22] Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805)
Ueno, Makoto
Okusaka, Takuji
Mizusawa, Junki
Takashima, Atsuo
Morizane, Chigusa
Ikeda, Masafumi
Hamamoto, Yasuo
Ishii, Hiroshi
Hara, Hiroki
Fukutomi, Akira
Furukawa, Masayuki
Nagase, Michitaka
Yamaguchi, Taketo
Yamao, Kenji
Nakamori, Shoji
Ioka, Tatsuya
Iguchi, Haruo
Miyakawa, Hiroyuki
Boku, Narikazu
Furuse, Junji
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[23] DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
Hyung, Jaewon
Cho, Hyungwoo
Kim, Hyung-Don
Park, Young Soo
Moon, Meesun
Ryu, Min-Hee
Kang, Yoon-Koo
GASTRIC CANCER, 2023, 27 (1) : 110 - 117
[24] DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
Jaewon Hyung
Hyungwoo Cho
Hyung-Don Kim
Young Soo Park
Meesun Moon
Min-Hee Ryu
Yoon-Koo Kang
Gastric Cancer, 2024, 27 : 110 - 117
[25] A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer
Higashijima, Jun
Tokunaga, Takuya
Yoshimoto, Toshiaki
Eto, Shohei
Kashihara, Hideya
Takasu, Chie
Nishi, Masaaki
Yoshikawa, Kozo
Okitsu, Hiroshi
Ishikawa, Masashi
Miyake, Hidenori
Yagi, Toshiyuki
Kono, Toru
Shimada, Mitsuo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 875 - 882
[26] Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer A Randomized Clinical Trial
Yu, Jiren
Gao, Yuan
Chen, Li
Wu, Dan
Shen, Qianyun
Zhao, Zhicheng
Liu, Weihuai
Yang, Hanliang
Zhang, Qi
Wang, Xinbao
Hu, Ping
Zheng, Zhiqiang
Wang, Xianfa
Liu, Hongjun
Xu, Zekuan
Yan, Zhilong
Wu, Yingjie
Jin, Mingjuan
Zhang, Qing
Liu, Xiaosun
Zhu, Kankai
Shou, Chunhui
JAMA NETWORK OPEN, 2022, 5 (02)
[27] Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
Lee, Keun-Wook
Chung, Ik-Joo
Ryu, Min-Hee
Park, Young Iee
Nam, Byung-Ho
Oh, Ho-Suk
Lee, Kyung Hee
Han, Hye Sook
Seo, Bong-Gun
Jo, Jae-Cheol
Lee, Hyo Rak
Kim, Jin Won
Park, Sook Ryun
Cho, Sang Hee
Kang, Yoon-Koo
GASTRIC CANCER, 2021, 24 (01) : 156 - 167
[28] Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
Keun-Wook Lee
Ik-Joo Chung
Min-Hee Ryu
Young Iee Park
Byung-Ho Nam
Ho-Suk Oh
Kyung Hee Lee
Hye Sook Han
Bong-Gun Seo
Jae-Cheol Jo
Hyo Rak Lee
Jin Won Kim
Sook Ryun Park
Sang Hee Cho
Yoon-Koo Kang
Gastric Cancer, 2021, 24 : 156 - 167
[29] Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).
Iwasaki, Yoshiaki
Terashima, Masanori
Mizusawa, Junki
Katayama, Hiroshi
Nakamura, Kenichi
Katai, Hitoshi
Yoshikawa, Takaki
Ito, Yuichi
Kaji, Masahide
Kimura, Yutaka
Hirao, Motohiro
Yamada, Makoto
Kurita, Akira
Takagi, Masakazu
Gotoh, Masahiro
Takagane, Akinori
Yabusaki, Hiroshi
Hirabayashi, Naoki
Sano, Takeshi
Sasako, Mitsuru
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients
Mitsuhiko Ota
Hiroshi Saeki
Hideo Uehara
Yoshiko Matsuda
Satoshi Tsutsumi
Tetsuya Kusumoto
Hisateru Yasui
Yasunari Ubukata
Shohei Yamaguchi
Hiroyuki Orita
Naoki Izawa
Saburo Kakizoe
Mototsugu Shimokawa
Tomoharu Yoshizumi
Yoshihiro Kakeji
Masaki Mori
Eiji Oki
International Journal of Clinical Oncology, 2023, 28 : 1166 - 1175

← 1 2 3 4 5 →